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Abstract: Decitabine is a hydrophilic drug that acts by hypomethylating DNA. Decitabine is 
used in Europe for the treatment of acute myeloid leukemia (AML) in patients aged 65 years. 
However, it can only be administered intravenously due to very low oral bioavailability and a large 
distribution volume. Oral administration would allow outpatient treatment, improving quality of life 
and reducing treatment costs. The present study proposes to develop lipid nanocapsules (LNCs), 
originally designed for lipophilic drugs, to encapsulate decitabine. Two different formulations of 
LNCs were designed: LNCs based on a high proportion of Transcutol® HP (THP-LNCs) and LNCs 
associated with a mixture of Transcutol® HP and Tween® 80 (THP-T80-LNCs). The second formu-
lation had a diameter of 26.5±0.5 nm, high encapsulation efficiency (85%), and a drug payload 
of 472±64 µg/mL. Decitabine-loaded THP-T80-LNC cytotoxicity was evaluated on two AML 
cell lines depending on their decitabine resistance: HEL (not resistant) and HL-60 (resistant). The 
permeability of decitabine-loaded THP-T80-LNCs was also evaluated on Caco-2 cell monolayers. 
Decitabine cytotoxicity against HEL and HL-60 was higher when decitabine was loaded in THP-
T80-LNCs than when free. Apparent permeability on Caco-2 cell monolayers was also increased, 
suggesting a potentially useful formulation to increase the oral bioavailability of decitabine.
Keywords: lipid nanocapsules, acute myeloid leukemia, decitabine, nanomedicine, nanopar-
ticles, oral administration, Caco2 cells
Introduction
In 2012, the incidence of leukemia was estimated to be 2.5% of all cancers, excluding 
non-melanoma skin cancer, according to the International Agency for Research on 
Cancer. Acute myeloid leukemia (AML) is a common acute leukemia in older patients, 
accounting for 30% of adult leukemias.1 AML is caused by the overproduction of 
myeloblasts that accumulate in bone marrow, peripheral blood, and tissues, resulting 
in reduced production of normal bone marrow cells.
Comorbidities are often present in older AML patients, and best supportive care is 
preferred to the intensive chemotherapy used for younger patients. Thus, fewer patients 
aged 60 years with newly diagnosed AML, associated with comorbidities, receive 
chemotherapy.2 In 2012, the European Medicines Agency (EMA) granted a marketing 
authorization, valid throughout the European Union, for the use of decitabine in AML 
patients aged 65 years who are not candidates for standard induction chemotherapy due 
to age or comorbidities. Decitabine was previously approved in 2006 by the US Food and 
Drug Administration (FDA) for de novo or secondary myelodysplastic syndrome.
Decitabine (5-aza-2′ deoxycytidine) was first described more than 40 years ago.3 It 
is a cytidine deoxynucleoside analog, which acts by inhibiting DNA methyltransferase, 
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inducing DNA hypomethylation. To be active, decitabine 
needs to be transported into cells by an equilibrative-
nucleoside-transport (hENT) system and converted into 
its triphosphate form. Decitabine is a hydrophilic drug 
(log P=−2.2), with a short half-life (25 minutes), and is 
sensitive to harsh conditions. For example, the glycosidic 
bond of azanucleosides is cleaved under acidic conditions, 
and there is a rapid opening of the 5-azacytosine ring under 
alkaline conditions.3,4
The European marketed formulation of decitabine 
(Dacogen®; Janssen-Cilag, Beerse, Belgium) is a sterile 
freeze-dried powder. Excipients are potassium dihydrogen 
phosphate, sodium hydroxide, and hydrochloric acid for pH 
adjustment. There is no specific tissue targeting, resulting in 
wide distribution,5 suggesting that decitabine is distributed 
into tissues outside the plasma compartment.
In AML, decitabine is administered via intravenous (IV) 
infusion, every day, for 5 days at 20 mg/m², every 4 weeks. 
The increase of median survival (2.7 months) is modest, but 
was considered to be meaningful by the EMA in the context of 
AML in older patients without alternative treatment.6 A Phase II 
clinical trial (NCT01786343) is ongoing with modified 
dosing schedules to increase the cytotoxic activity of the drug.
Various approaches have been developed to modify 
pharmacokinetic parameters of decitabine to enhance its oral 
bioavailability and therapeutic index, including the use of 
nanocarriers. For example, Vijayaraghavalu and Labhasetwar 
have tested decitabine-loaded nanogels for their ability to 
protect decitabine from degradation and enhance its intra-
cellular uptake.7 Cui et al have developed decitabine con-
jugates incorporated into micelles to enhance the activity 
of an associated drug, temozolomide, against glioblastoma 
cells,8 Neupane et al9,10 have developed lipid-decitabine 
conjugate nanoparticles for oral administration. All these 
studies used organic solvents for chemical modification 
of the drug or the process of nanoparticle formulation.9,10 
However, organic solvents may cause new toxicities in 
clinical applications.
Replacing IV administration of decitabine with oral 
administration may improve treatment acceptability by 
patients and facilitate the administration with possible 
treatment at home with no requirement of a medical team.11 
Various parameters influence the oral absorption of drugs, 
such as intestinal permeability, solubility in aqueous media, 
and stability in intestinal fluids.
Our laboratory has developed lipid nanocapsules (LNCs) 
based on a solvent-free process and prepared by a low energy 
phase inversion process.12 Lipophilic drugs have already been 
encapsulated into LNCs, such as paclitaxel, docetaxel, SN38, 
etoposide, hydroxytamoxifen, miltefosine, or a ferrocenyl 
complex.12–17 Hydrophilic drugs, such as fondaparinux18 
or DNA and siRNA,19,20 have also been encapsulated, and 
reverse micelles associated with LNCs containing doxoru-
bicin hydrochloride or erlotinib hydrochloride have been 
developed.21,22 Encapsulation into LNCs has modified the 
pharmacokinetic parameters of DNA when encapsulated in 
stealth LNCs,20 or of miltefosine, an antischistosomal drug, 
by increasing its time to reach the maximal concentration 
and increasing its activity against Shistosoma mansoni.16 
Moreover, several publications have reported the advantages 
of LNCs for oral administration. It has been shown that LNCs 
are able to protect encapsulated SN38 in intestinal fluids and 
enhance its permeability across a Caco-2 cell monolayer.14 
LNCs are also able to modify oral bioavailability of encap-
sulated drugs, such as paclitaxel and fondaparinux.18,23
The aim of the present study was to adapt the formulation 
of LNCs to encapsulate decitabine and evaluate its efficacy in 
AML cell models. The permeability of encapsulated decitabine 
across an intestinal barrier model was evaluated to estimate the 
potential oral administration of the formulation developed.
Materials and methods
chemicals
Decitabine was purchased from LC Laboratories® (Woburn, 
MA, USA). Labrafac® WL1349 (caprylic-capric acid triglyc-
erides), Labrafil® M1944CS (oleoyl macrogol-6 glycerides), 
Peceol® (glycerol mono-oleates), and Transcutol® HP (THP) 
(highly purified diethylene glycol monoethyl ether) were kindly 
provided by Gattefossé (Saint-Priest, France). Lipoïd® S75-3 
(soybean lecithin: 69% phosphatidylcholine and 10% phos-
phatidylethanolamine) and Kolliphor® HS15 (mixture of free 
polyethylene glycol [PEG] 660 and PEG 660 hydroxystear-
ate) were kindly supplied by Lipoïd® and BASF, respectively 
(Ludwigshafen, Germany). Deionized water was obtained 
from a Milli-Q plus system (Merck-Millipore, Darmstadt, 
Germany). Sodium chloride and disodium hydrogen phosphate 
were purchased from Prolabo (Fontenay-Sous-Bois, France) 
and sucrose was purchased from Merck-Millipore. Sodium 
phosphate dibasic dodecahydrate, potassium dihydrogen 
phosphate, formic acid, ammonium acetate, Triton® X-100, 
Tween® 80, Span® 80, and formic acid were obtained 
from Sigma-Aldrich (St Quentin-Fallavier, France). Cap-
tex® 8000 (glyceryl tricaprylate) was a gift from Abitec 
Corp. (Saint-Quentin Fallavier, France).
Absolute ethanol, methanol ULC/MS grade, acetonitrile, 
and LC-MS grade water were purchased from Biosolve 
(Dieuze, France). Acetone was purchased from VWR 
(Fontenay-sous-Bois, France).
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analytical methods
analysis of decitabine by ultra-high-performance 
liquid chromatography (UPlc-UV)
An UPLC-UV method was developed to quantify decitabine 
in solubility and formulation studies. The apparatus consisted 
of an UPLC Acquity® H-Class Bio (Waters, Saint-Quentin-
en-Yvelines, France) composed of a quaternary solvent 
manager, a sample manager with the temperature fixed at 
4°C, a photo diode array detector, operating between 200 and 
400 nm, and a column manager with the temperature fixed 
at 25°C. The system was managed by Empower® 3 software 
(Waters). The column used was an Acquity® UPLC HSS T3 
2.1×50 mm, 1.8 µm (Waters). Detection was fixed at 239 nm. 
The mobile phase consisted of a gradient elution (Table S1) 
composed of a mixture of water (A) and methanol (B). The 
injection volume was set to 5 µL.
Decitabine solutions were systematically prepared by 
dissolving a sufficient quantity in a phosphate-buffered 
solution (PBS, pH 7.0) composed of a 50:50 (v/v) mixture of 
dibasic sodium phosphate dodecahydrate solution (26 mM) 
and potassium dihydrogen phosphate (67 mM). The runtime 
of the analysis was 10 minutes.
The method was validated according to ICH Q2 R1 
standards.24 Linearity of the method was evaluated by a cali-
bration curve composed of seven calibration points between 
2.5 and 50 µg/mL. Calibration curves were performed three 
times on 3 different days. The correlation coefficient (r²) of 
the mean calibration curve had to be 0.995.
Accuracy of the method was assessed by making nine 
determinations of three concentrations (5, 20, and 40 µg/mL) 
three times a day, for 3 days. Accuracy was determined as 
the difference between the mean measured value and the 
accepted true value. Accuracy, for each concentration, had 
to be 5% from the accepted true value to be accepted.
Repeatability was assessed by measuring a 10 µg/mL 
solution six times a day. Intermediate precision was evalu-
ated by measuring this solution six times a day for 3 days. 
Repeatability and intermediate precision were measured 
using the standard deviation, which had to be 5% to be 
accepted.
The limit of detection (LOD) and limit of quantification 
(LOQ) were based on the standard deviation of the response 
and the slope and were determined as follows:
 
LOD
S
LOQ
S
= =3 3 10. σ σand
 
where σ is the standard deviation of the response of 10 blanks 
and S is the slope of the calibration curve.
analysis of decitabine by lc-Ms/Ms
An LC-MS/MS method was developed to quantify lower 
amounts of decitabine within the linear range of UPLC-UV, 
in formulations and in vitro decitabine release studies. The 
LC-MS/MS method was developed on an Alliance® 2695 
system (Waters) with a 150×2 mm, 3 µm Nucleodur® HILIC 
column (Macherey Nagel, Hoerdt, France), containing an 
ammonium-sulfonic acid–modified silica. The temperature 
was fixed at 25°C. The mobile phase consisted of a mixture 
of (A) 0.1% formic acid in 10 mM ammonium acetate and 
(B) 0.1% formic acid in acetonitrile. A gradient mode was 
used (Table S2). The injection volume was set at 6 µL. The 
total HPLC effluent was directed into a Quattro Micro® 
triple quadrupole mass spectrometer (Waters). Ionization 
was achieved using electrospray in positive ion mode. The 
mass spectrometer was operated in multiple reaction moni-
toring mode. The (M − H) + m/z transition for decitabine 
was 229.0113.0. The entire system was controlled by 
Masslynx® software (Waters).
Decitabine was diluted in methanol to obtain a 7-point 
calibration curve between 2.5 and 500 ng/mL. The 
LC-MS/MS method was also validated according to the ICH 
Q2 R1 validation method.24 The same validation protocol was 
applied as that used for the UPLC-UV method. Accuracy was 
determined at three concentrations (10, 100, and 400 ng/mL) 
and precision at 200 ng/mL. The requirements were the same 
as for the UPLC-UV method (5% for each).
LOD and LOQ were based on the standard deviation of 
the response and the slope, as described above.
solubility study
Decitabine (5 mg) was added to 1 g of oil, co-solvent, sur-
factant, or a mixture of them. Preparations were sonicated at 
room temperature for 2 hours or placed at 25°C under magnetic 
stirring for 72 hours to facilitate solubilization. For solubility 
studies on mixtures of oil, surfactant, and co-solvent, magnetic 
stirring was performed at 50°C for 2 hours or the mixtures were 
sonicated for 2 hours at room temperature. All preparations 
were then centrifuged at 9,000× g for 10 minutes. Supernatants 
were collected and filtered using a 0.22 µm Millex® (Merck-
Millipore). Filtrates were analyzed by the UPLC-UV method 
described above. When the solubility was over 2.0 mg/g, the 
experiment was repeated two more times.
lNc formulations
Formulation of lNcs with Transcutol® hP 
(ThP-lNcs)
LNCs were obtained according to the formulation process 
developed in our laboratory, based on a phase inversion 
 
In
te
rn
at
io
na
l J
ou
rn
al
 o
f N
an
om
ed
ici
ne
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
19
3.
52
.4
0.
1 
on
 2
4-
No
v-
20
17
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
International Journal of Nanomedicine 2017:12submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
8430
Briot et al
process12 and a formulation using THP was prepared.14,15 
This formulation was modified to increase the proportion 
of THP to improve the quantity of decitabine incorporated 
into the decitabine-loaded formulation. Concentrations of 
Lipoïd® S75-3, Kolliphor® HS15, and NaCl in water before 
the dilution step were set to 2.9% (w/w), 19.4% (w/w), and 
1.9% (w/w), respectively. A ternary diagram was used to plot 
the possible proportions of Labrafac® WL1349, Labrafil® 
M1944CS, and THP. A formulation was considered to be 
acceptable if the size of the particle was 100 nm and the 
polydispersity index (PI) 0.20.
Briefly, Labrafac® WL1349, Labrafil® M1944CS, and 
THP were mixed with Lipoïd® S75-3 by magnetic stirring and 
heated to 80°C. The mixture was cooled to room temperature 
and other components were added: Kolliphor® HS15, NaCl, 
deionized water. Three heating cycles under magnetic stir-
ring were performed between 40°C and 90°C. During the 
last cooling cycle, when the inversion phase was detected, 
tempering was induced with 5 mL 4°C water. Magnetic stir-
ring was maintained for 5 minutes at room temperature and 
the suspension of THP-LNCs was filtered using a 0.22 µm 
polyethersulfone filter (Merck-Millipore) to remove potential 
residual components.
The optimal formulation, corresponding to the maximum 
quantity of THP, was selected.
Decitabine-loaded ThP-lNcs
Decitabine was first solubilized in THP at a concentration 
of 2.5 mg/g by ultrasonication for 2 hours, and decitabine-
solubilized in THP was then incorporated into the optimized 
formulation (as described above) during the last cooling 
cycle, just before tempering.
Formulation of lNcs with a mixture of ThP and 
Tween® 80 (ThP-T80-lNcs)
First, a mixture of THP and Tween® 80 (THP-T80) (w/w) was 
made. Then, an LNC formulation composed of Kolliphor® 
HS15 (39.3% w/w), NaCl (1.8% w/w), Labrafac® WL1349 
(17.2% w/w), and water (41.7% w/w) was prepared by three 
heating cycles under magnetic stirring performed between 
65°C and 95°C. During the last cooling cycle, at 85°C, the 
THP-T80 mixture was introduced (30% w/w total composi-
tion) and tempering was induced at 75°C with 5 mL 4°C 
water. Magnetic stirring was maintained for 5 minutes at 
room temperature.
Decitabine-loaded ThP-T80-lNcs
A sufficient quantity of decitabine was incorporated under 
magnetic stirring at 50°C for 2 hours in THP-T80 mixture 
to obtain a concentration of 4.2 mg/g. Decitabine was then 
incorporated into the THP-T80-LNC formulation (described 
in “Formulation of LNCs with a mixture of THP and Tween® 
80 (THP-T80-LNCs)” section) during the last cooling cycle, 
just before tempering.
characterization of lNc formulations
size and PI measurement
Mean particle size and PI were determined by dynamic light 
scattering on a Zetasizer® Nano serie DTS 1060 (Malvern 
Instruments S.A., Worcestershire, UK). PI was used as a 
measure of size distribution. The formulations were diluted 
1:60 (v/v) in deionized water. Three consecutive measure-
ments were performed.
Transmission electronic microscopy (TeM)
Size and morphology of blank THP-T80-LNCs were inves-
tigated using a JEOL JEM 1400 (JEOL, Croissy Sur Seine, 
France) operating at 120 kV. A sample of particle suspension 
was placed on a copper grid and water was evaporated at 
40°C for one night prior to imaging by TEM.
Determination of encapsulation efficiency 
and drug loading
Total (free and encapsulated) quantities of decitabine in the 
formulations were evaluated by UPLC-UV (THP-LNCs) or 
LC-MS/MS (THP-T80-LNCs). Formulations were diluted 
1:20 (v/v) in Triton® X-100 diluted 10 times in PBS pH 7.0 
for the UPLC-UV method, and 1:5,000 (v/v) in methanol for 
the LC-MS/MS method. Triton® X-100 and methanol were 
used to release decitabine from LNCs by breaking them.
The formulations were subjected to ultracentrifugation 
in a sucrose gradient to separate encapsulated and free-
decitabine. The formulation (200 µL) was first placed in a 
tube, followed by a slow addition of 400 µL of a 50% (w/v) 
sucrose solution, 600 µL of a 20% (w/v) sucrose solution, 
and finally 600 µL deionized water. The tubes were centri-
fuged at 214,000× g for 1.5 hours at 4°C in an Optima TLX 
ultracentrifuge (Beckman, Villepinte, France), equipped 
with a TLS 55 rotor.
After 1.5 hours, each fraction was collected and 100 µL 
of each diluted 1:10 v/v in Triton® X-10 and decitabine 
quantification performed by the UPLC-UV method for 
decitabine-loaded THP-LNCs. The encapsulation efficiency 
was determined by LC-MS/MS for decitabine-loaded THP-
T80-LNCs. Each fraction was diluted in water instead of 
Triton® X-10 and then in methanol 1:20 (v/v).
Decitabine not encapsulated in the formulation was 
found in the sediment fraction after ultracentrifugation, 
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corresponding to the 50% sucrose (w/v) fraction, whereas 
encapsulated decitabine was found in the supernatant 
fraction, corresponding to the aqueous fraction.
The encapsulation efficiency was defined as:
Encapsulation efficiency 
Total decitabine Decitabine n
(%) =
− ot encapsulated
Total decitabine
×100
 
The experimental drug payload was defined as:
Drug payload g mL g mL
Encapsulation e
( ) Total decitabine ( )µ µ=
× fficiency (%)  
Freeze-drying of decitabine-loaded ThP-T80-lNcs
After formulation, a 40% (w/v) sucrose solution (cryo-
protectant) was introduced to THP-T80-LNCs at a 1:1 v/v 
ratio and a freeze-drying cycle performed (Alpha 1–4 LSC, 
Christ, Darmstadt, Germany). Formulations were conserved 
at −20°C. The water volume removed after freeze-drying 
was evaluated by weighing formulations before and after 
the process. Mean particle size, PI, encapsulation efficiency, 
and drug loading were determined after reconstitution with 
200 µL water.
In vitro release study
The release kinetics of decitabine-loaded THP-T80-LNCs 
were evaluated in PBS pH 7.4. About 1 mL of decitabine-
loaded THP-T80-LNCs was placed in a Float-a-Lyzer® 
(Spectrum labs, CA, USA) (100 kDa) completely submerged 
in a beaker containing 150 mL PBS to reach the “sink” condi-
tions, at 37°C for 24 hours, under agitation. A free-decitabine 
solution, with a concentration equivalent to the concentration 
of decitabine-loaded THP-T80-LNC was used as a control. 
A 40 µL sample of the PBS was removed at defined time 
points and replaced with PBS. The experiment was performed 
in triplicate. Samples were quantified by LC-MS/MS.
Decitabine stability in human plasma
Decitabine stability in human plasma from healthy volunteers 
was performed to evaluate its relative degradation over time. 
Decitabine-loaded THP-T80-LNCs (100 µL) were mixed 
with plasma (1.6 mL) at 37°C for 6 hours, under agitation. 
A free-decitabine solution, with a concentration equivalent to 
the concentration of decitabine-loaded THP-T80-LNCs was 
used as a control. A 40 µL sample of plasma was removed 
at 1, 4, and 6 hours and mixed with acetonitrile. Samples 
were then centrifuged 10 minutes at 9,500× g (Centrifuge 
5810 R; Eppendorf, Montesson, France). Supernatant was 
then quantified by LC-MS/MS after a dilution in methanol 
(1/10). The experiment was performed in triplicate.
cell experiments
In vitro cell viability
The toxicity of decitabine-loaded THP-T80-LNCs was com-
pared to free-decitabine on the human erythroleukemia cell 
line (HEL) and human promyelocytic leukemia cells (HL-60) 
(LGC Standards, Molsheim, France). HEL cells were main-
tained in Roswell Park Memorial Institute 1640 (RPMI) 
medium (LGC Standards), containing 10% fetal bovine 
serum (FBS) (Gibco, Fisher Scientific France, Illkirch, 
France) and 1% antibiotics (Sigma-Aldrich) and HL-60 cells 
were maintained in Iscove’s Modified Dulbecco’s Medium 
(LGC Standards), containing 20% FBS and 1% antibiotics, as 
recommended by the supplier. Each cell line was maintained 
in a humidified incubator with an atmosphere containing 5% 
CO
2
 at 37°C.
For viability assays, cells were plated in 96-well plates 
at densities of 1×104 cells/well (HEL) or 1.5×104 cells/well 
(HL-60). After 24 hours, cells were treated with free-decit-
abine or decitabine-loaded THP-T80-LNCs to reach decit-
abine concentrations of 1–1,000 nM (HEL) or 200–4,000 nM 
(HL-60). Blank THP-T80-LNCs were also tested with the 
same excipient concentrations as for decitabine-loaded 
THP-T80-LNCs. Cells cultured with medium alone were 
considered to correspond to 100% viability. After 72 hours, 
plates were centrifuged, culture medium removed, and 
cell pellets frozen at −80°C until assayed. Cell survival 
was estimated with the CyQUANT® cell proliferation 
assay kit, according to the manufacturer’s instructions 
(Fisher Scientific). Three independent experiments were 
conducted, each with quadruplicate samples. The concen-
tration giving 50% inhibition (IC50) of the cell viability 
was calculated according to Reed and Muench.25
In vitro transepithelial transport
The human colon adenocarcinoma cell line (Caco-2) (ATCC, 
Manassas, VA, USA) was used at passage 30. Cells were 
cultured in Dulbecco’s Modified Eagle’s Medium (DMEM, 
high glucose; Lonza, Verviers, Belgium), supplemented with 
15% (v/v) FBS, 1% (v/v) non-essential amino acids (Sigma-
Aldrich), 1% (v/v) sodium pyruvate (Sigma-Aldrich), and 
1% antibiotics in a humidified incubator with an atmosphere 
of 5% CO
2
 at 37°C. Cells were plated in a Transwell® cell 
culture chamber (Corning Costar, NY, USA) at a density of 
1×105 cells/insert (0.4 µm pore size, 1.12 cm² growth area). 
The culture medium (0.5 mL per insert and 1.5 mL per well) 
was replaced every 2 days for the first 2 weeks and every 
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day for the last 7 days. After 21 days, cell monolayers were 
obtained and used.
Before the experiment, cells were washed with Hanks 
Balanced Salt Solution (HBSS) (Lonza) and mixed with 
10 mM Hepes (Sigma-Aldrich), twice, for 10 minutes at 
37°C. The transepithelial electrical resistance (TEER) of 
the monolayer was assessed before and after the experiment 
using a Millicell® ER system (Merck-Millipore). Only cell 
monolayers with a TEER over 250 Ω/cm² were used.
Free-decitabine or decitabine-loaded in THP-T80-LNCs 
(20 µM, 0.5 mL) were then added to the cell monolayers and 
1.5 mL HBSS-Hepes buffer added to the basolateral side 
(n=4 for each condition).
After 2 and 4 hours in a humidified incubator at 37°C, 
5% CO
2
, samples from the apical and basolateral side 
were removed and the decitabine concentration evaluated 
by LC-MS/MS. The apparent permeability coefficient 
(P
app
) was then calculated according to the following 
equation:
 
P
dQ
dtapp
= × 1
AQi  
where dQ/dt is the rate of drug appearance on the basolateral 
side (µg/s); Qi is the initial quantity of decitabine on the api-
cal side (µg); A is the surface area of the monolayer (cm²).
statistical analysis
Results are expressed as mean values ± standard deviation 
(SD) or standard error of the mean (SEM) for the cell studies. 
A Kruskal–Wallis test was used for statistical analysis, 
p0.05 was considered to be statistically significant.
Results
Validation of analytical methods
UPlc-UV method
The retention time of decitabine was 1.4 minutes, the peak 
was symmetric and well defined (Figure S1). The mean cali-
bration curve of the method for the range of 2.5–50 µg/mL, 
determined on 3 different days was:
 y x= × − ×1 237 10 1 168 10
4 4. .  
where y is the area under the curve and x is the amount of 
decitabine.
The correlation coefficient (r²) of the mean calibration 
curve was 0.997, indicating that the method was linear. 
The accuracy of the method was 2.9%, 2.8%, and 0.6% 
at 5, 20, and 40 µg/mL, respectively. Repeatability of the 
method was systematically inferior to 4.0% and intermediate 
precision 2.6%. Accuracy, repeatability, and intermediate 
precision were thus compatible with the requirements.
The LOD and LOQ were 0.1 and 0.3 µg/mL, 
respectively.
lc-Ms/Ms method
The retention time of decitabine was 3.5 minutes (Figure S1). 
The linearity of the method between 2.5 and 500 ng/mL 
gave an r² value that was systematically 0.998. The mean 
calibration curve of the method determined on 3 different 
days was:
 y x= −43 988 8 184, ,  
where y is the area under the curve and x is the amount of 
decitabine.
The accuracy of the method was 2.8%, −4.4%, and −1.5% 
at 10, 100, and 400 ng/mL respectively. Repeatability of the 
method was systematically inferior to 5.0% and intermediate 
precision 3.7%. The accuracy, repeatability, and intermediate 
precision were compatible with the requirements.
The LOD and LOQ were 0.04 and 0.11 ng/mL, 
respectively.
solubility studies
Decitabine solubility in several oils, co-solvents, and 
surfactants were evaluated at 0.5% w/w by an ultrasonic 
method for 2 hours or magnetic stirring for 72 hours, at 
room temperature. For an excipient mixture, magnetic stir-
ring was performed for 2 hours at 50°C instead of 72 hours 
at 25°C. Among the nine oils, co-solvents, surfactants, or 
mixtures, only the THP and THP-T80 mixture were able to 
solubilize decitabine (Table 1). Moreover, concentrations 
after 72 hours were systematically less than those after 
2 hours. THP, a co-solvent already used in LNC formula-
tions solubilized 2.5 mg/g of decitabine. The THP-T80 
mixture provided maximum solubilization of decitabine 
(4.7 mg/g).
THP and THP-T80 mixtures were used for further for-
mulation investigations.
Decitabine formulations
Two decitabine formulations were tested: decitabine-loaded 
THP-LNCs and decitabine-loaded THP-T80-LNCs.
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The first formulation designed was a new THP-LNC 
formulation with a higher proportion of THP to increase the 
quantity of decitabine in the decitabine-loaded formulation. 
Nineteen formulations were tested (Figure 1). The ternary 
diagram shows that no formulation with a size 100 nm 
and/or a PI 0.20 was obtained when the proportion of 
Labrafac® WL1349 20%. It was necessary to increase 
the proportion of Labrafil® M1944CS and decrease that of 
Labrafac® WL1349 to increase the proportion of THP.
Finally, formulation 18 (F18) was chosen for its size 
of 100 nm (32.6 nm) and PI of 0.20 (0.08). The quantity 
of Lipoïd® S75-3 was reduced from 150 to 100 mg, because 
filtration was difficult using a 0.22 µm filter. The final opti-
mized proportions were 24.7% (w/w) THP, 16.5% (w/w) 
Labrafil® M1944CS, 2.0% (w/w) Lipoïd® 75-3, 19.6% (w/w) 
Table 1 solubility of decitabine in various oils, surfactants, or 
co-solvents after 2 hours in an ultrasonic bath at room temper-
ature or 72 hours under magnetic stirring at 25°c (2 hours at 
50°c for excipient mixtures)
Medium Ultrasonic bath
(mg/g)
Magnetic stirring
(mg/g)
captex® 8000 0.0 0.0
ThP* 2.5±0.2 0.3
Tween® 80 0.8 0.5
Peceol® 0.0 0.0
span® 80 0.0 0.0
Labrafil® M1944cs 0.2 0.1
ThP-T80 (50:50 w/w)* 1.5 4.7±0.4
Tween® 80/labrafac® Wl1349 1.0 1.0
span® 85/labrafac® Wl1349 0.0 0.4
Notes: The measurement was repeated three times if the first solubility was 
2.0 mg/g. results are expressed as the mean ± sD (*).
Abbreviations: ThP, Transcutol® hP; T80, Tween® 80.
Figure 1 Ternary diagram of the optimization of ThP-lNcs.
Notes: green points correspond to formulations for which the PI was 0.20 and the size 100 nm and red points to those for which the size was 100 nm and/or the PI 
was 0.20. Formulation F18 was the most highly optimized.
Abbreviations: lNc, lipid nanocapsule; ThP, Transcutol® hP; PI, polydispersity index.
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Kolliphor® HS15, 2.0% (w/w) NaCl, and 35.3% (w/w) water. 
The volume of water for the tempering was 5 mL. The size 
and PI of blank THP-LNCs were 33.6±1.6 nm and 0.09±0.01, 
respectively (Table 2).
Decitabine was solubilized in THP and added to the for-
mulation during the last cooling step to obtain the decitabine-
loaded THP-LNC formulation. Size, PI, total decitabine 
concentration, encapsulation efficiency, and drug loading 
are presented in Table 2. Decitabine-loaded THP-LNCs had 
a mean diameter of 33.6 nm and a PI 0.10, indicating a 
narrow size distribution.
Recovery of the decitabine incorporated in the formula-
tion was 96%±11%. However, the encapsulation efficiency 
was too low (15%) and drug loading was insufficient, a 
new LNC formulation was thus developed. The initially 
developed LNCs with Labrafac® WL1349 were used, and a 
mixture of THP and Tween® 80 was added during the last 
cooling cycle, just before tempering, to obtain the THP-T80-
LNC formulation.
Blank THP-T80-LNCs had a size of 30 nm and a PI 
of 0.10, indicating a narrow size distribution (Table 2). 
This size was confirmed by TEM analysis, and a spherical 
morphology of LNCs was observed (Figure 2). Decitabine 
was solubilized in the THP-T80 mixture and added dur-
ing the last cooling cycle, before tempering, to obtain the 
decitabine-loaded THP-T80-LNC formulations. Size, PI, 
total decitabine concentration, encapsulation efficiency, 
and drug loading are presented in Table 2. The size and 
PI of decitabine-loaded formulations were not modified 
relative to the blank formulations, as for the THP-LNCs. 
Recovery of the incorporated decitabine in the formulation 
was 96%±10%, and the drug payload was 472±64 µg/g of 
the formulation. The THP-T80-LNC formulation was used 
for in vitro drug release and cell experiments.
Decitabine is sensitive to hydrolysis. Storage of decitabine- 
loaded THP-T80-LNCs at 4°C for 4 days decreased the 
total decitabine concentration to 118±3 µg/mL. The ability 
of THP-T80-LNCs to support freeze-drying was tested, in 
order to avoid water contact in the formulation. Freeze-drying 
removed approximately 75% of the water volume from the 
formulation.
The size and PI of freeze-dried decitabine-loaded THP-
T80-LNCs were analyzed for 5 months. After reconstitution 
in water, the size, PI, and total decitabine concentration were 
similar to the values obtained before freeze-drying at the 
different times tested (Figure 3). However, the encapsula-
tion efficiency and drug payload were reduced by a factor 
of 9 (Table 2).
In vitro release of the decitabine
The release of decitabine-loaded THP-T80-LNCs relative 
to free-decitabine in PBS under submersion conditions 
was performed (Figure 4). There was significantly a slower 
release from decitabine-loaded THP-T80-LNCs than free-
decitabine into the PBS, with no burst effect. Approximately 
70% of the decitabine was released from THP-T80-LNCs 
after 24 hours and reached a plateau, whereas a total release 
of free-decitabine was observed, indicating retention of 
decitabine in THP-T80-LNCs. After 24 hours, the residual 
concentration of decitabine into the Float-a-Lyzer® device 
Table 2 Physico-chemical characteristics of blank and decitabine-loaded lNc formulations
LNC formulations Size (nm) PI Total decitabine  
concentration (µg/mL)
Encapsulation 
efficiency (%)
Drug payload 
(µg/mL)
Blank lNcs-ThP 33.6±1.6 0.09±0.01 – – –
lNcs-ThP 33.6±1.0 0.08±0.01 297±34 15±5 44±16
Blank ThP-T80-lNcs 26.7±1.2 0.08±0.02 – – –
ThP-T80-lNcs 26.5±0.5 0.08±0.01 537±54 88±3 472±64
Freeze-dried ThP-T80-lNcs 26.0±0.4 0.09±0.01 555±75 9±2 51±12
Note: Size, PI, encapsulation efficiency, drug payload, and total decitabine concentration in the formulation are expressed as the mean ± sD (n=3).
Abbreviations: lNc, lipid nanocapsule; ThP, Transcutol® hP; T80, Tween® 80; PI, polydispersity index.
Figure 2 TeM micrographs of blank ThP-T80-lNcs.
Note: The scale bars represent 200 nm (A), 100 nm (B), or 50 nm (C) and (D).
Abbreviations: lNc, lipid nanocapsule; ThP, Transcutol® hP; T80, Tween® 80.
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for the decitabine-loaded THP-T80-LNCs was estimated to 
be 26±12%. The initial quantity of decitabine incorporated 
during the experiment was thus recovered.
Decitabine stability in human plasma
An enzyme degradation study of free-decitabine and 
decitabine-loaded THP-T80-LNCs in human plasma from 
healthy volunteers where cytidine deaminase is presented was 
performed. Decitabine loaded in THP-T80-LNCs was pro-
tected from cytidine deaminase degradation (Figure 5). Fifty 
percent of free-decitabine was degraded after 4 hours in human 
plasma, whereas a degradation of 35% was observed when 
decitabine was encapsulated in THP-T80-LNCs. This protec-
tion by THP-T80-LNCs was also observed after 6 hours.
In vitro cytotoxicity of decitabine-loaded 
ThP-T80-lNcs on aMl cell lines
Two AML cell lines were selected to evaluate the cyto-
toxicity of decitabine-loaded THP-T80-LNCs: HEL and 
HL60. HEL cells are more sensitive to decitabine than 
HL-60.26 Cell viability profiles after 3 days of treatment 
with blank THP-T80-LNCs, free-decitabine, or decitabine-
loaded THP-T80-LNCs are presented in Figure 6. Neither 
low concentrations (1–50 nM) of free-decitabine nor 
decitabine-loaded THP-T80-LNCs altered the growth of 
HEL cells. Exposure to 100 nM decitabine decreased HEL 
cell survival. The IC
50
 for decitabine-loaded THP-T80-
LNCs was 670 nM and 1,000 nM for free-decitabine 
(Figure 6). There was no change in the viability of HEL 
???? ??
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Figure 3 stability study of freeze-dried blank ThP-T80-lNcs over time.
Notes: Formulations were freeze dried and kept frozen at −20°c (n=3). size and PI were measured after water reconstitution.
Abbreviations: lNc, lipid nanocapsule; ThP, Transcutol® hP; T80, Tween® 80; PI, polydispersity index.
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Figure 4 Decitabine release profile from THP-T80-LNCs in PBS pH 7.4.
Notes: release of the decitabine loaded in ThP-T80-lNcs was compared to that 
of free-decitabine (n=3, data are shown as the mean ± sD). *p-value 0.05.
Abbreviations: lNc, lipid nanocapsule; ThP, Transcutol® hP; T80, Tween® 80; 
PI, polydispersity index.
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Figure 5 Stability profile of free-decitabine and decitabine-loaded THP-T80-LNCs 
in human plasma (n=3, data are shown as the mean ± sD).
Note: *p-value 0.05 for decitabine-loaded ThP-T80-lNcs versus free-decitabine.
Abbreviations: lNc, lipid nanocapsule; ThP, Transcutol® hP; T80, Tween® 80.
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cells in the presence of blank THP-T80-LNCs, even at 
high concentrations.
The HL-60 cell survival study confirmed the resistance 
of these cells to free-decitabine, as cell survival only slightly 
decreased (20%) at concentrations 1,000 nM. Decitabine-
loaded THP-T80-LNCs were more toxic, decreasing HL-60 
viability with an IC50 of 1,537 nM. Blank THP-T80-LNCs also 
lowered HL60 viability, but significantly less than decitabine-
loaded THP-T80-LNCs, resulting in an IC50 of 471 versus 259 
µg/mL for decitabine-loaded THP-T80-LNCs (Figure 6).
cellular transport across caco-2-cell 
monolayers
Permeability of free-decitabine and decitabine-loaded THP-
T80-LNCs were evaluated across Caco-2 cell monolayers 
after 2 and 4 hours (Figure 7). There was no difference 
in permeability between free-decitabine and encapsulated 
decitabine after 2 hours. After 4 hours, the permeability of 
Caco-2-cell monolayers to decitabine-loaded THP-T80-
LNCs was significantly higher than that after 2 hours and to 
that of free-decitabine (p-value =0.039).
Discussion
Decitabine is a hypomethylating agent recently authorized 
for the treatment of older AML patients. However, daily IV 
administration of decitabine is a very restrictive treatment. 
Contrary to EMA, FDA has not approved decitabine for 
AML treatment due to its lack of efficacy (the drug was only 
approved for myelodysplasic syndrome).6 This limitation may 
be due to its short half-life. Incorporation of decitabine in an 
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Figure 6 cell viability following exposure of hel (A) and hl-60 (B) cells to various concentrations of free-decitabine, blank ThP-T80-lNcs, or decitabine-loaded ThP-
T80-lNcs.
Notes: Data are expressed as the mean ± seM (n=12). results obtained for hel and hl-60 cells with culture medium alone were considered to correspond to 100% 
survival. *P-value 0.05 for free-decitabine versus decitabine-loaded ThP-T80-lNcs; **P-value 0.05 for decitabine-loaded ThP-T80-lNcs versus blank ThP-T80-lNcs; 
***P-value 0.05 for blank ThP-T80-lNcs versus 100% survival.
Abbreviations: lNc, lipid nanocapsule; ThP, Transcutol® hP; T80, Tween® 80; seM, standard error of the mean.
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LNC formulation may overcome this limitation. Moreover, 
decitabine treatment is only available via IV administration, 
mainly due to its low permeability, whereas the oral route 
would be more convenient for patients. Indeed, the oral route 
is compatible with treatment taken at home without the help 
of a nurse,11 reducing treatment costs relative to those for IV 
administration. An LNC formulation of decitabine may allow 
modification of the administration route.
The development of decitabine-LNC formulations 
requires validated analytical methods to characterize formula-
tions and perform in vitro evaluations. Two analytical methods 
were developed and validated according to the ICH Q2 R1:24 
an UPLC-UV method and a LC-MS/MS method. Compared 
to a previous published analytical method using HPLC-UV,27 
the UPLC-UV method was able to reduce the runtime analysis 
(to 10 minutes versus 45 minutes). The UPLC-UV method 
for decitabine was linear in the µg/mL range with an LOQ 
of 0.3 µg/mL. This was not sufficiently sensitive for in vitro 
experiments. Thus, an LC-MS/MS method was developed 
and validated. A normal solid phase was used instead of 
the reverse C
18 
phase used in the UPLC-UV method, to 
increase the sensitivity of detection. Indeed, the obtained 
LOQ was 0.11 ng/mL, an increase in sensitivity of 25-fold.
In comparison with other nanocarriers used to encap-
sulate decitabine,7–10 two free-organic solvent formulations 
were developed. Moreover, no chemical modification of 
decitabine was performed, thus not precluding its activity. 
Among Captex® 8000, Labrafil® M 1944 CS, Span® 80, THP, 
and Tween® 80 used to produce LNCs,14,15,21–23 only THP or a 
mixture of THP-T80 were able to solubilize decitabine. The 
solubility of decitabine in THP has been previously shown 
by Neupane et al.10
THP has already been used in LNC formulations to encap-
sulate active lipophilic pharmaceutical ingredients, such as 
SN38 and etoposide, with high drug payloads.14,15 Overall, 
decitabine-LNC prototype formulations were investigated 
to obtain optimal decitabine loading. The quantity of THP 
was increased into the formulations to increase the quantity 
of incorporated decitabine. Moreover, during solubility 
study, a lower decitabine concentration in excipients was 
observed after 72 hours than after 2 hours. This may be due 
to the thermosensitivity of decitabine.4,28 To avoid a poten-
tial degradation of decitabine during the temperature cycles 
required for LNC formulation, decitabine was solubilized 
in THP in an ultrasonic bath at room temperature and added 
during the last cooling cycle, just before tempering with 
cold water. The addition of the drug during the last cooling 
cycle has already been used to encapsulate siRNA, known 
to be sensitive to high temperatures.29 After formulation, the 
recovery of the decitabine was over 95%, confirming the 
protection of decitabine from high temperatures during 
the formulation process. Decitabine-loaded THP-LNCs had 
a size of 33.6±1.6 nm and a drug payload of 44±16 µg/mL, 
which was too low for therapeutic efficacy. In AML, the 
decitabine dosing schedule is 20 mg/m² per day, requiring a 
volume over 450 mL/m² with this formulation. A minimum 
drug payload of 200 µg/mL (corresponding to 100 mL/m²) 
would be required for therapeutic application.
The solubility of decitabine is higher in THP-T80 
mixtures than in THP alone. Thus, an association between 
THP, Tween® 80, and LNCs was tested to increase drug 
loading. A similar method using a mixture of Labrafac® 
WL1349 and Span® 85 was previously used to encapsulate 
doxorubicin hydrochloride and erlotinib hydrochloride.21,22 
However, decitabine was insoluble in a mixture of Labrafac® 
WL1349 and Span® 85, and these compounds were replaced 
by a mixture of THP and Tween® 80. Decitabine-loaded 
THP-T80-LNCs had a size of 26.5±0.5 nm, which is smaller 
than the formulations developed by Vrignaud et al, combining 
Span® 85 and Labrafac® WL1349 (LNC size of 80 nm).21,22 
They showed that the size of the final formulation was affected 
by the reverse formulation composition and correlated with 
the hydrophilic-lipophilic balance (HLB) of the surfactant 
used.21 Indeed, the HLB of Tween® 80 is 15, whereas it is 1.8 
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Figure 7 apparent permeability of decitabine after 2 and 4 hours of incubation with 
20 µM free-decitabine or 20 µM decitabine-loaded ThP-T80-lNcs (n=4).
Notes: Data are expressed as the mean ± seM; *P-value 0.05 for free-decitabine 
versus decitabine-loaded ThP-T80-lNcs; **P-value 0.05 for 2 versus 4 hours.
Abbreviations: lNc, lipid nanocapsule; ThP, Transcutol® hP; T80, Tween® 80; 
seM, standard error of the mean.
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for Span® 85. Moreover, THP, an ethylene oxide derivative, 
is more hydrophilic than Labrafac® W1349, a triglyceride 
compound, confirming the hypothesis of Vrignaud et al on the 
strong correlation between the size of LNCs and hydrophilic-
ity of the mixture associated with LNCs.22 A drug payload 
of 472±64 µg/mL and an encapsulation efficiency over 85% 
were finally obtained. This drug payload corresponds to an IV 
infusion volume of 42 mL/m² per day for AML treatment and 
could be considered for therapeutic application. This level 
of drug loading was compared to that of previous studies, 
in which nanostructured lipid carriers were developed. Drug 
loading ranged from 6% to 7% w/w for decitabine-loaded 
nanogels7 and was 8.54%±2.65% in lipid-based nanocar-
riers developed by Neupane et al.10 The size obtained in 
our formulation was less than that of previously developed 
formulations, ranging from 80 to 200 nm.9,10,30,31 Paillard et 
al have demonstrated that the number of LNCs internalized 
into cells is inversely proportional to their size,32 suggesting 
that the size obtained for the THP-T80-LNC formulation 
could favor internalization. Moreover, no organic solvent 
was used and no decitabine-chemical modification was made 
in the THP-T80-LNC formulations, in contrast to previous 
formulations developed to encapsulate decitabine.9,10,30,31 
The use of organic solvents may hamper the transfer of 
such strategies to a clinical scale. Due to these interesting 
properties, decitabine-loaded THP-T80-LNCs were selected 
and further characterizations were performed.
The decitabine was degraded when THP-T80-LNCs 
were stored in suspension at 4°C, confirming its instability 
in water.4,28 A freeze-drying of decitabine-loaded THP-T80-
LNCs was then performed. The choice of cryoprotectant is 
fundamental to conserve LNC properties after thawing. Dif-
ferent cryoprotectants, including glucose, lactose, maltose, 
mannitol, mannose, sucrose, and trehalose were tested (data 
not shown). Among all cryoprotectants assayed, a 40% w/w 
sucrose solution added in a 1:1 v/v ratio with the formulation 
gave the best results, with no change in terms of size, PI, 
or total decitabine concentration. A high concentration of 
sucrose preserved the size of the particles after the freeze 
drying process, and a disaccharide, such as sucrose, worked 
better than monosaccharides.33 Contrary to previous obser-
vations on the LNC-freeze-drying process in the presence 
of trehalose, no modification of size was observed, despite 
the absence of lecithin, and THP-T80-LNCs can be freeze-
dried.34 This observation was confirmed by Saliou et al who 
demonstrated the interest of PEG chains to act as stabilizers 
during freeze-drying.15 Freeze-drying conserved the physi-
cal characteristics of THP-T80-LNCs and preserved the 
total decitabine concentration, despite a residual content 
of water (25% of the initial quantity), probably insufficient 
to hydrolyze decitabine during storage. The drug payload 
was however drastically decreased after this process. Thus, 
this method was not selected to stabilize the formulation, 
and currently, decitabine-loaded THP-T80-LNCs must be 
formulated extemporaneously.
It is known that high doses of decitabine are toxic in the 
clinic, whereas prolonging low doses are more effective, 
especially in AML patients, due to their poor hematological 
status.35,36 Encapsulation of a drug in carriers (microparticles or 
nanoparticles) is a strategy largely used to control drug release 
and decrease side effects. A release study using a Float-a-Lyzer® 
device, in PBS pH 7.4, in sink conditions, was performed to 
study the release kinetics of decitabine from LNCs. Decitabine 
was more slowly released from dialysis bags in the case of the 
decitabine-loaded THP-T80-LNCs than for free-decitabine, 
with no burst effect. After 24 hours, ~70% of the decitabine 
was released from THP-T80-LNCs and reached a plateau, 
whereas the non-encapsulated decitabine was completely 
released. A very similar comparative profile was observed for 
previous formulations of decitabine nanoconjugates developed 
by Neupane et al.9,10 After 24 hours, 80% of the drug was 
released from nanocarriers, whereas it was fully released after 
4 hours when not entrapped in nanocarriers. The slowed release 
of loaded decitabine confirms its retention in THP-T80-LNC 
nanocarriers. This could limit antitumor activity if this is con-
firmed in vivo. Although the in vitro experimental conditions 
tested have been largely described and used in the literature, 
they are not fully representative of in vivo conditions, and thus, 
this result should be confirmed in vivo.
The slowed release of decitabine encapsulated into THP-
T80-LNCs, which prolonged the contact of decitabine with 
cells, may be responsible for the stronger cytotoxic effect of 
decitabine-loaded THP-T80-LNCs relative to free-decitabine 
on non-resistant (HEL) and resistant (HL-60) AML cells. 
The improved cytotoxic effect may also be explained by the 
ability of LNCs to be internalized by cells via endocytosis.32 
LNCs could thus facilitate the translocation of decitabine 
across the cellular membrane, which is generally carried 
out by nucleoside transporters, such as hENT1.26,37,38 Thus, 
both the pathways could be used: free-drug through hENT 1 
transport and decitabine-loaded THP-T80-LNCs through the 
endocytosis pathway. This property was also demonstrated, 
in various cancer cell lines, with a lipophilic-gemcitabine 
derivate loaded in solid lipid nanoparticles.39 A cell toxicity 
of THP-T80-LNCs was observed at high concentrations on 
HL-60 cells and was probably due to the presence of THP 
and Kolliphor® HS15 in THP-T80-LNCs composition, well 
known to be toxic at high concentration.40–42
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Finally, older AML patients receive decitabine treatment 
through IV administration. The oral route may allow outpa-
tient treatment and improve their quality of life. Moreover, 
it would help to reduce treatment costs, because oral admin-
istration does not require a qualified team. Nevertheless, the 
oral bioavailability of decitabine described in the literature is 
very low, 3.9%–14%,43 probably due to its low permeability 
(log P=−2.2) and its high hepatic metabolism limiting its 
half-life and oral administration.
Previous experiments have demonstrated the potential of 
LNCs for the oral administration of drugs. Apparent perme-
ability of paclitaxel across a Caco-2 cell monolayer when 
encapsulated into LNCs, increased by a factor of 3.5,44 
which is consistent with an in vivo study that demonstrated a 
threefold improvement in the oral bioavailability of paclitaxel 
over that of the injectable solution.23 The strong correlation 
between the in vitro and in vivo models led us to study the 
apparent permeability of decitabine-loaded THP-T80-LNCs 
across Caco-2 cell monolayers. THP-T80-LNCs increased 
the transport of decitabine by a factor of 30 over that of 
free-decitabine. The mechanism used by THP-T80-LNCs to 
increase the Papp transport of decitabine across Caco-2 cell 
monolayers is presently unknown. Neupane et al developed 
a lipid-decitabine conjugate, which was encapsulated into 
nanoparticles, and then they performed an ex vivo permeation 
study on a non-everted gut sac model.9 The Papp coefficient 
increased by a factor of 4 over that of a decitabine solution. 
According to authors, lipids and surfactants used in the 
formulations (Tween® 80, Poloxamer 188, Labrasol®, and 
Solutol® HS15) were able to inhibit P-glycoprotein, explain-
ing the increase in permeability. However, no publication has 
demonstrated that decitabine is a substrate of P-glycoprotein.5 
Lavelle et al administered a cytidine deaminase inhibitor, 
tetrahydrouridine, 1 hour before the oral administration of 
decitabine.45 Oral bioavailability was improved by a factor 
of 9, suggesting an important effect of cytidine deaminase on 
decitabine degradation. Indeed, decitabine is rapidly metabo-
lized by cytidine deaminase, which is its main degradation 
pathway.46 Cytidine deaminase is present in human plasma. 
A decitabine stability study was also performed in human 
plasma, which showed that THP-T80-LNCs were able to 
protect decitabine from cytidine deaminase degradation. 
Roger et al showed that LNCs were uptaken by Caco-2 cells 
mainly via active endocytic processes and more particularly 
via clathrin-dependent and caveolae-dependent transport 
mechanisms.44 Moreover, the same authors observed that the 
integrity of LNCs is preserved after Caco-2 internalization 
through fluorescence resonance energy transfer analysis.47 
These data suggest that the protection of the decitabine 
by THP-T80-LNCs against cytidine deaminase and the 
internalization of LNCs by Caco-2 cells may improve gas-
trointestinal crossing of the drug. Given that LNCs remain 
intact throughout Caco-2 passage, the enhanced cytotoxic 
activity of encapsulated decitabine against AML cells may 
be conserved after intestinal absorption.
Conclusion
A formulation combining a mixture of THP-T80 and LNCs 
was able to efficiently encapsulate a hydrophilic drug, 
decitabine, without chemical modification of the drug or 
the use of organic solvents. The drug payload was over 
450 µg/mL and the toxicity against two AML cell lines 
of the decitabine loaded in THP-T80-LNCs was enhanced 
over that of free-decitabine. The increased permeability 
of decitabine-loaded THP-T80-LNCs across a Caco-2 cell 
monolayer suggests the potential use of this formulation 
for oral administration.
Studies to evaluate the activity and pharmacokinetic 
parameters of decitabine-loaded THP-T80-LNCs in in vivo 
models of AML should now be considered.
Acknowledgments
The authors are very grateful to the Ligue contre le Cancer 
and particularly to the Maine et Loire and Charente-Maritime 
committees for their financial support.
The authors thank the SCIAM (Service Commun 
d’Imageries et d’Analyses Microscopiques) of Angers 
(France) for the TEM analysis.
Disclosure
The authors report no conflicts of interest in this work.
References
1. Rodriguez-Abreu D, Bordoni A, Zucca E. Epidemiology of hematological 
malignancies. Ann Oncol. 2007;18(1):i3–i8.
2. Alibhai SM, Leach M, Minden MD, Brandwein J. Outcomes and quality 
of care in acute myeloid leukemia over 40 years. Cancer. 2009;115(13): 
2903–2911.
3. Stresemann C, Lyko F. Modes of action of the DNA methyltrans-
ferase inhibitors azacytidine and decitabine. Int J Cancer. 2008;123(1): 
8–13.
4. Lin KT, Momparler RL, Rivard GE. High-performance liquid chro-
matographic analysis of chemical stability of 5-aza-2′-deoxycytidine. 
J Pharm Sci. 1981;70(11):1228–1232.
5. European Medicines Agency. Dacogen: summary of product character-
istics. 2017. Available from: http://www.ema.europa.eu/docs/en_GB/
document_library/EPAR_-_Product_Information/human/002221/
WC500133569.pdf. Accessed June 1, 2017.
6. Nieto M, Demolis P, Behanzin E, et al. The European Medicines Agency 
Review of Decitabine (Dacogen) for the treatment of adult patients with 
acute myeloid leukemia: summary of the scientific assessment of the 
committee for medicinal products for human use. Oncologist. 2016; 
21(6):692–700.
 
In
te
rn
at
io
na
l J
ou
rn
al
 o
f N
an
om
ed
ici
ne
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
19
3.
52
.4
0.
1 
on
 2
4-
No
v-
20
17
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
International Journal of Nanomedicine 2017:12submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
8440
Briot et al
 7. Vijayaraghavalu S, Labhasetwar V. Efficacy of decitabine-loaded 
nanogels in overcoming cancer drug resistance is mediated via sustained 
DNA methyltransferase 1 (DNMT1) depletion. Cancer Lett. 2013; 
331(1):122–129.
 8. Cui Y, Naz A, Thompson DH, Irudayaraj J. Decitabine nanoconjugate 
sensitizes human glioblastoma cells to temozolomide. Mol Pharm. 
2015;12(4):1279–1288.
 9. Neupane YR, Sabir MD, Ahmad N, Ali M, Kohli K. Lipid drug con-
jugate nanoparticle as a novel lipid nanocarrier for the oral delivery 
of decitabine: ex vivo gut permeation studies. Nanotechnology. 2013; 
24(41):415102–415113.
10. Neupane YR, Srivastava M, Ahmad N, Kumar N, Bhatnagar A, Kohli K. 
Lipid based nanocarrier system for the potential oral delivery of 
decitabine: formulation design, characterization, ex vivo, and in vivo 
assessment. Int J Pharm. 2014;477(1–2):601–612.
11. Roger E, Lagarce F, Garcion E, Benoit JP. Biopharmaceutical param-
eters to consider in order to alter the fate of nanocarriers after oral 
delivery. Nanomedicine (Lond). 2010;5(2):287–306.
12. Heurtault B, Saulnier P, Pech B, Proust JE, Benoit JP. A novel phase 
inversion-based process for the preparation of lipid nanocarriers. Pharm 
Res. 2002;19(6):875–880.
13. Huynh NT, Passirani C, Saulnier P, Benoit JP. Lipid nanocapsules: 
a new platform for nanomedicine. Int J Pharm. 2009;379(2):201–209.
14. Roger E, Lagarce F, Benoit JP. Development and characterization of 
a novel lipid nanocapsule formulation of Sn38 for oral administration. 
Eur J Pharm Biopharm. 2011;79(1):181–188.
15. Saliou B, Thomas O, Lautram N, et al. Development and in vitro evalua-
tion of a novel lipid nanocapsule formulation of etoposide. Eur J Pharm 
Sci. 2013;50(2):172–180.
16. Eissa MM, El-Moslemany RM, Ramadan AA, Amer EI, El-Azzouni MZ, 
El-Khordagui LK. Miltefosine lipid nanocapsules for single dose oral 
treatment of Schistosomiasis mansoni: a preclinical study. PLoS One. 
2015;10(11):e0141788.
17. Laine AL, Clavreul A, Rousseau A, et al. Inhibition of ectopic glioma 
tumor growth by a potent ferrocenyl drug loaded into stealth lipid 
nanocapsules. Nanomedicine. 2014;10(8):1667–1677.
18. Ramadan A, Lagarce F, Tessier-Marteau A, et al. Oral fondaparinux: 
use of lipid nanocapsules as nanocarriers and in vivo pharmacokinetic 
study. Int J Nanomedicine. 2011;6:2941–2951.
19. Messaoudi K, Saulnier P, Boesen K, Benoit JP, Lagarce F. Anti-
epidermal growth factor receptor siRNA carried by chitosan-
transacylated lipid nanocapsules increases sensitivity of glioblastoma 
cells to temozolomide. Int J Nanomedicine. 2014;9:1479–1490.
20. Morille M, Montier T, Legras P, et al. Long-circulating DNA lipid nano-
capsules as new vector for passive tumor targeting. Biomaterials. 2010; 
31(2):321–329.
21. Vrignaud S, Anton N, Gayet P, Benoit JP, Saulnier P. Reverse micelle-
loaded lipid nanocarriers: a novel drug delivery system for the sustained 
release of doxorubicin hydrochloride. Eur J Pharm Biopharm. 2011; 
79(1):197–204.
22. Vrignaud S, Hureaux J, Wack S, Benoit JP, Saulnier P. Design, optimization 
and in vitro evaluation of reverse micelle-loaded lipid nanocarriers con-
taining erlotinib hydrochloride. Int J Pharm. 2012;436(1–2):194–200.
23. Peltier S, Oger JM, Lagarce F, Couet W, Benoit JP. Enhanced oral 
paclitaxel bioavailability after administration of paclitaxel-loaded lipid 
nanocapsules. Pharm Res. 2006;23(6):1243–1250.
24. International Conference on Harmonization. Validation of analytical 
procedures: text and methodology (Q2 R1). 2005. Available from: http://
www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Qual-
ity/Q2_R1/Step4/Q2_R1__Guideline.pdf. Accessed February 1, 2017.
25. Reed LJ, Muench H. A simple method of estimating fifty per cent 
endpoints. Am J Epidemiol. 1938;27(3):493–497.
 26. Qin T, Jelinek J, Si J, Shu J, Issa JP. Mechanisms of resistance to 5-aza-2′-
deoxycytidine in human cancer cell lines. Blood. 2009;113(3):659–667.
27. Neupane YR, Srivastava M, Ahmad N, Soni K, Kohli K. Stability indi-
cating RP-HPLC method for the estimation of decitabine in bulk drug 
and lipid based nanoparticles. Int J Pharm Sci Res. 2014;7:294–302.
28. Hua W, Ierardi T, Lesslie M, Hoffman BT, Mulvana D. Development and 
validation of a HILIC-MS/MS method for quantification of decitabine 
in human plasma by using lithium adduct detection. J Chromatogr B. 
2014;969:117–122.
29. David S, Resnier P, Guillot A, Pitard B, Benoit JP, Passirani C. siRNA 
LNCs – a novel platform of lipid nanocapsules for systemic siRNA 
administration. Eur J Pharm Biopharm. 2012;81(2):448–452.
30. Li SY, Sun R, Wang HX, et al. Combination therapy with epigenetic-
targeted and chemotherapeutic drugs delivered by nanoparticles to 
enhance the chemotherapy response and overcome resistance by breast 
cancer stem cells. J Control Release. 2015;205:7–14.
31. Su X, Wang Z, Li L, et al. Lipid-polymer nanoparticles encapsulat-
ing doxorubicin and 2′-deoxy-5-azacytidine enhance the sensitivity 
of cancer cells to chemical therapeutics. Mol Pharm. 2013;10(5): 
1901–1909.
32. Paillard A, Hindre F, Vignes-Colombeix C, Benoit JP, Garcion E. The 
importance of endo-lysosomal escape with lipid nanocapsules for drug 
subcellular bioavailability. Biomaterials. 2010;31(29):7542–7554.
33. Howard MD, Lu X, Jay M, Dziubla TD. Optimization of the lyophiliza-
tion process for long-term stability of solid-lipid nanoparticles. Drug 
Dev Ind Pharm. 2012;38(10):1270–1279.
34. Dulieu C, Bazile D. Influence of lipid nanocapsules composition on 
their aptness to freeze-drying. Pharm Res. 2005;22(2):285–292.
35. Karahoca M, Momparler RL. Pharmacokinetic and pharmacodynamic 
analysis of 5-aza-2′-deoxycytidine (decitabine) in the design of its dose-
schedule for cancer therapy. Clin Epigenetics. 2013;5(1):3.
36. He PF, Zhou JD, Yao DM, et al. Efficacy and safety of decitabine in 
treatment of elderly patients with acute myeloid leukemia: a systematic 
review and meta-analysis. Oncotarget. 2017;8(25):41498–41507.
37. Arimany-Nardi C, Errasti-Murugarren E, Minuesa G, et al. Nucleoside 
transporters and human organic cation transporter 1 determine the cel-
lular handling of DNA-methyltransferase inhibitors. Br J Pharmacol. 
2014;171(16):3868–3880.
38. Ueda K, Hosokawa M, Iwakawa S. Cellular uptake of decitabine by 
equilibrative nucleoside transporters in HCT116 Cells. Biol Pharm 
Bull. 2015;38(8):1113–1119.
39. Lansakara PD, Rodriguez BL, Cui Z. Synthesis and in vitro evaluation 
of novel lipophilic monophosphorylated gemcitabine derivatives and 
their nanoparticles. Int J Pharm. 2012;429(1–2):123–134.
40. Sullivan DW Jr, Gad SC, Julien M. A review of the nonclinical safety 
of Transcutol(R), a highly purified form of diethylene glycol monoethyl 
ether (DEGEE) used as a pharmaceutical excipient. Food Chem Toxicol. 
2014;72:40–50.
41. Le Roux G, Moche H, Nieto A, Benoit JP, Nesslany F, Lagarce F. Cyto-
toxicity and genotoxicity of lipid nanocapsules. Toxicol In Vitro. 2017; 
41:189–199.
42. Maupas C, Moulari B, Beduneau A, Lamprecht A, Pellequer Y. Surfactant 
dependent toxicity of lipid nanocapsules in HaCaT cells. Int J Pharm. 
2011;411(1–2):136–141.
43. Liu D. Recent advances in myelodysplasia: update from 2011 ASH 
annual meeting. J Hematol Oncol. 2012;5:A4.
44. Roger E, Lagarce F, Garcion E, Benoit JP. Lipid nanocarriers improve 
paclitaxel transport throughout human intestinal epithelial cells by 
using vesicle-mediated transcytosis. J Control Release. 2009;140(2): 
174–181.
45. Lavelle D, Vaitkus K, Ling Y, et al. Effects of tetrahydrouridine on phar-
macokinetics and pharmacodynamics of oral decitabine. Blood. 2012; 
119(5):1240–1247.
46. Issa JP, Roboz G, Rizzieri D, et al. Safety and tolerability of guadecit-
abine (SGI-110) in patients with myelodysplastic syndrome and acute 
myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 
study. Lancet Oncol. 2015;16(9):1099–1110.
47. Roger E, Gimel JC, Bensley C, Klymchenko AS, Benoit JP. Lipid 
nanocapsules maintain full integrity after crossing a human intestinal 
epithelium model. J Control Release. 2017;253:11–18.
 
In
te
rn
at
io
na
l J
ou
rn
al
 o
f N
an
om
ed
ici
ne
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
19
3.
52
.4
0.
1 
on
 2
4-
No
v-
20
17
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
International Journal of Nanomedicine 2017:12 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
8441
New decitabine nanocarriers for the treatment of acute myeloid leukemia
Supplementary materials
Table S1 gradient elution of the UPlc-UV method
Time (minutes) Phase A (%) Phase B (%) Flow (mL/minutes)
2.5 100 0 0.6
4 20 80 0.6
6 20 80 0.6
8 100 0 0.3
9 100 0 0.6
10 100 0 0.6
Note: Phase a was composed of water and phase B of methanol.
Abbreviation: UPlc-UV, ultra-high-performance liquid chromatography.
Table S2 gradient elution of the lc-Ms/Ms method
Time (minutes) Phase A (%) Phase B (%) Flow (mL/minutes)
0.00 20 80 0.200
6.00 28 72 0.200
6.10 28 72 0.300
7.00 20 80 0.300
12.00 20 80 0.300
Note: Mobile Phase a was composed of a mixture of ammonium acetate 10 mM and 0.1% formic acid v/v, and mobile phase B acetonitrile and 0.1% formic acid v/v.
Figure S1 (Continued)
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Figure S1 chromatograms of a 40 µg/ml decitabine solution analyzed by the UPlc-UV method (A), a 20 ng/ml decitabine solution analyzed by the lc-Ms/Ms method (B), 
and mean calibration curves of the UPlc-UV method (C) and lc-Ms/Ms method (D).
Abbreviation: UPlc-UV, ultra-high-performance liquid chromatography.
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